Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland Tumors

International Journal of Surgical Pathology

Volumn 24, Issue 5, 2016, Pages 394-400

  Rössle, Matthias ^a   Cathomas, Gieri ^b   Bonapace, Laura ^c   Sachs, Melanie ^b   Dehler, Silvia ^d   Storz, Martina ^e   Huber, Gerhard ^e   Moch, Holger ^e   Junt, Tobias ^c   Mertz, Kirsten D ^b  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Cancer Registry Zurich   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Biomarker; Immunohistochemistry; Interleukin 33; Prognosis; Salivary gland; Tissue microarray

Indexed keywords

INTERLEUKIN 33; TUMOR MARKER; IL33 PROTEIN, HUMAN;

ACINAR CELL CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA; CHILD; CONTROLLED STUDY; EPITHELIAL MYOPEPITHELIAL CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYOEPITHELIOMA; MYOEPITHELIUM CELL; ONCOCYTIC CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CANCER; SALIVARY GLAND TUMOR; TISSUE MICROARRAY; WARTHIN TUMOR; BIOSYNTHESIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SALIVARY GLAND NEOPLASMS; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-33; MALE; MIDDLE AGED; PROGNOSIS; SALIVARY GLAND NEOPLASMS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84976521757     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896916633856     Document Type: Article

References (30)

1. de Oliveira FA, Duarte EC, Taveira CT, Maximo AA, de Aquino EC, Alencar RC, Vencio EF,. Salivary gland tumor: a review of 599 cases in a Brazilian population. Head Neck Pathol. 2009; 3: 271-275.
2. Lawal AO, Adisa AO, Kolude B, Adeyemi BF, Olajide MA,. A review of 413 salivary gland tumours in the head and neck region. J Clin Exp Dent. 2013; 5: e218-e222.
3. Lima RA, Tavares MR, Dias FL, et al.Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg. 2005; 133: 702-708.
4. Seethala RR,. Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol. 2011; 18: 29-45.
5. Ardestani SK, Inserra P, Solkoff D, Watson RR,. The role of cytokines and chemokines on tumor progression: a review. Cancer Detect Prev. 1999; 23: 215-225.
6. Seruga B, Zhang H, Bernstein LJ, Tannock IF,. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008; 8: 887-899.
7. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G,. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007; 179: 2051-2054.
8. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA,. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007; 179: 2551-2555.
9. Liew FY, Pitman NI, McInnes IB,. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010; 10: 103-110.
10. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C,. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007; 40: 216-225.
11. Schmitz J, Owyang A, Oldham E, et al.IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23: 479-490.
12. Bianchi ME,. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007; 81: 1-5.
13. Carriere V, Roussel L, Ortega N, et al.IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A. 2007; 104: 282-287.
14. Kuchler AM, Pollheimer J, Balogh J, et al.Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008; 173: 1229-1242.
15. Moussion C, Ortega N, Girard JP,. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin"? PLoS One. 2008; 3: e3331.
16. Chen SF, Nieh S, Jao SW, et al.The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013; 231: 180-189.
17. Ishikawa K, Yagi-Nakanishi S, Nakanishi Y, et al.Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Auris Nasus Larynx. 2014; 41: 552-557.
18. Liu J, Shen JX, Hu JL, Huang WH, Zhang GJ,. Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front Immunol. 2014; 5: 141.
19. Mertz KD, Mager LF, Wasmer MH, et al.The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology. 2015; 26: e1062966.
20. Storz-Schweizer M, Moch H,. Tissue microarrays and biomarker validation. In: Cheng L, Zhang DY, eds. Molecular Genetic Pathology. New York, NY: Humana Press; 2008: 133-140.
21. Sedhom MA, Pichery M, Murdoch JR, et al.Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2013; 62: 1714-1723.
22. Kempf W, Zollinger T, Sachs M, et al.Granulomas are a source of interleukin-33 expression in pulmonary and extrapulmonary sarcoidosis. Hum Pathol. 2014; 45: 2202-2210.
23. Balkwill F, Coussens LM,. Cancer: an inflammatory link. Nature. 2004; 431: 405-406.
24. Burkholder B, Huang RY, Burgess R, et al.Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta. 2014; 1845: 182-201.
25. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S,. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol. 2008; 181: 2898-2906.
26. Horn-Ross PL, Ljung BM, Morrow M,. Environmental factors and the risk of salivary gland cancer. Epidemiology. 1997; 8: 414-419.
27. Zarbo RJ,. Salivary gland neoplasia: a review for the practicing pathologist. Mod Pathol. 2002; 15: 298-323.
28. Rostan O, Arshad MI, Piquet-Pellorce C, Robert-Gangneux F, Gangneux JP, Samson M,. Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases. Infect Immun. 2015; 83: 1738-1748.
29. Siva S, MacManus M, Kron T, et al.A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer. PLoS One. 2014; 9: e109560.
30. Sponheim J, Pollheimer J, Olsen T, et al.Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol. 2010; 177: 2804-2815.